Bacteria and bacterial derivatives as delivery carriers for immunotherapy

Kang, Sae-Ryung; Nguyen, Dinh-Huy; Yoo, Su Woong; Min, Jung‐Joon

doi:10.1016/j.addr.2021.114085

Cited by 35 publications

(17 citation statements)

References 372 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous Gram-negative bacteria are reported to infect host cells that are dependent on the type III secretion system ( Ruano-Gallego et al, 2021 ; Sanchez-Garrido et al, 2021 ). This system is associated with bacterial invasion and intracellular growth, thereby affecting the efficiency of bacterial clearance and initial transient localization ( Kang et al, 2022 ). Given that invasion ability is one of the important factors determining bacterial cytotoxicity, the invasion ability of VNP20009 and ΔppGpp to cells was compared in vitro .…”

Section: Resultsmentioning

confidence: 99%

“…With the development of molecular biology and the deep understanding of the tumor immune microenvironments, BMCT has once again aroused the interest of researchers as a promising approach for cancer therapy. Hypoxia, vascular abnormalities, low pH, and necrotic areas are common features of solid tumors (Guo et al, 2020;Chen et al, 2021b;Kang et al, 2022), and they are the main barriers for traditional therapies. However, they provide favorable conditions for the targeting, colonization, and replication of some obligate or facultative anaerobes.…”

Section: Introductionmentioning

confidence: 99%

“…Hypoxia, vascular abnormalities, low pH, and necrotic areas are common features of solid tumors ( Guo et al, 2020 ; Chen et al, 2021b ; Kang et al, 2022 ), and they are the main barriers for traditional therapies. However, they provide favorable conditions for the targeting, colonization, and replication of some obligate or facultative anaerobes.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of Anticancer Activities and Biosafety Between Salmonella enterica Serovar Typhimurium ΔppGpp and VNP20009 in a Murine Cancer Model

Liu

Guo²,

Sun³

et al. 2022

Front. Microbiol.

Self Cite

View full text Add to dashboard Cite

Salmonella Typhimurium defective in guanosine 5′-diphosphate-3′-diphosphate (ppGpp) synthesis (ΔppGpp) is an attenuated strain with good biosafety and excellent anticancer efficacy. It has been widely applied in preclinical studies of anticancer therapy for various types of solid cancer. VNP20009 is another genetically modified auxotrophic strain with 108-kb deletion, purI−, msbB−, and many single nucleotide polymorphisms (SNPs); it has shown promising therapeutic efficacy in various preclinical tumor models and entered phase I clinical trials. Here, the invasion activities and virulence of ΔppGpp were obviously lower than those of the VNP20009 strain when tested with cancer cells in vitro. In addition, the MC38 tumor-bearing mice showed comparable cancer suppression when treated with ΔppGpp or VNP20009 intravenously. However, the ΔppGpp-treated mice showed 16.7% of complete cancer eradication and prolonged survival in mice, whereas VNP20009 showed higher toxicity to animals, even with equal tumor size individually. Moreover, we found decreased levels of inflammatory cytokines in circulation but strengthened immune boost in tumor microenvironments of ΔppGpp-treated mice. Therefore, the engineered ΔppGpp has high potential for cancer therapeutics, and it is a promising option for future clinical cancer therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of Anticancer Activities and Biosafety Between Salmonella enterica Serovar Typhimurium ΔppGpp and VNP20009 in a Murine Cancer Model

Liu

Guo²,

Sun³

et al. 2022

Front. Microbiol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is worth noting that trafficking and targeting of drugs by bacterial structures may involve mechanisms not necessarily dependent on extracellular drug delivery [11]. Mechanisms include fusion of the bacterial structure with cell membranes of the target cancer cells with subsequent release of their cargo inside the cytoplasmic space [73,74]. Uptake of bacterial ghosts by other types of cells such as antigen presenting cells [75] and conjunctival epithelial cells [76] has been reported.…”

Section: Discussionmentioning

confidence: 99%

Prodigiosin-Functionalized Probiotic Ghosts as a Bioinspired Combination Against Colorectal Cancer Cells

Saleh

Mahmoud

Eltaher

et al. 2022

Probiotics & Antimicro. Prot.

View full text Add to dashboard Cite

Lactobacillus acidophilus ghosts (LAGs) with the unique safety of a probiotic, inherent tropism for colon cells, and multiple bioactivities offer promise as drug carriers for colon targeting. Our objective was to evaluate LAGs functionalized with prodigiosin (PG), apoptotic secondary bacterial metabolite, as a bioinspired formulation against colorectal cancer (CRC). LAGs were prepared by a chemical method and highly purified by density gradient centrifugation. LAGs were characterized by microscopic and staining techniques as relatively small-sized uniform vesicles (≈1.6 µm), nearly devoid of cytoplasmic and genetic materials and having a negatively charged intact envelope. PG was highly bound to LAGs envelope, generating a physiologically stable bioactive entity (PG-LAGs), as verified by multiple microscopic techniques and lack of PG release under physiological conditions. PG-LAGs were active against HCT116 CRC cells at both the cellular and molecular levels. Cell viability data highlighted the cytotoxicity of PG and LAGs and LAGs-induced enhancement of PG selectivity for HCT116 cells, anticipating dose reduction for PG and LAGs. Molecularly, expression of the apoptotic caspase 3 and P53 biomarkers in HCT116 intracellular proteins was significantly upregulated while that of the anti-apoptotic Bcl-2 (B-cell lymphoma 2) was downregulated by PG-LAGs relative to PG and 5-fluorouracil. PG-LAGs provide a novel bacteria-based combination for anticancer biomedicine. Graphical abstract

show abstract

“…Consequently, antibacterial therapies that inhibit the growth of tumorigenic bacteria will be beneficial to cancer therapy. More recently, bacteria, as drug-delivery vehicles and immune modulators in tumor biotherapy, have attracted increasing attention with the progress of biotechnology and immunology thanks to their unique properties, including disease-site localization and therapeutic agent production ( Chen et al, 2021 ; Pan et al, 2021 ; Kang et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Recent advances in bacteria-mediated cancer therapy

Liang

Wang

Shao

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cancer is among the leading cause of deaths worldwide. Although conventional therapies have been applied in the fight against the cancer, the poor oxygen, low extracellular pH, and high interstitial fluid pressure of the tumor microenvironment mean that these treatments fail to completely eradicate cancer cells. Recently, bacteria have increasingly been considered to be a promising platform for cancer therapy thanks to their many unique properties, such as specific tumor-targeting ability, high motility, immunogenicity, and their use as gene or drug carriers. Several types of bacteria have already been used for solid and metastatic tumor therapies, with promising results. With the development of synthetic biology, engineered bacteria have been endowed with the controllable expression of therapeutic proteins. Meanwhile, nanomaterials have been widely used to modify bacteria for targeted drug delivery, photothermal therapy, magnetothermal therapy, and photodynamic therapy, while promoting the antitumor efficiency of synergistic cancer therapies. This review will provide a brief introduction to the foundation of bacterial biotherapy. We begin by summarizing the recent advances in the use of many different types of bacteria in multiple targeted tumor therapies. We will then discuss the future prospects of bacteria-mediated cancer therapies.

show abstract

Bacteria and bacterial derivatives as delivery carriers for immunotherapy

Cited by 35 publications

References 372 publications

Comparison of Anticancer Activities and Biosafety Between Salmonella enterica Serovar Typhimurium ΔppGpp and VNP20009 in a Murine Cancer Model

Comparison of Anticancer Activities and Biosafety Between Salmonella enterica Serovar Typhimurium ΔppGpp and VNP20009 in a Murine Cancer Model

Prodigiosin-Functionalized Probiotic Ghosts as a Bioinspired Combination Against Colorectal Cancer Cells

Recent advances in bacteria-mediated cancer therapy

Contact Info

Product

Resources

About